1. Academic Validation
  2. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4

Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4

  • Blood. 2013 Jul 11;122(2):272-81. doi: 10.1182/blood-2013-01-478966.
Miriam E Jaax 1 Krystin Krauel Thomas Marschall Sven Brandt Julia Gansler Birgitt Fürll Bettina Appel Silvia Fischer Stephan Block Christiane A Helm Sabine Müller Klaus T Preissner Andreas Greinacher
Affiliations

Affiliation

  • 1 Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt-Universität, Greifswald, Germany.
Abstract

The tight electrostatic binding of the chemokine Platelet Factor 4 (PF4) to polyanions induces heparin-induced thrombocytopenia, a prothrombotic adverse drug reaction caused by immunoglobulin G directed against PF4/polyanion complexes. This study demonstrates that nucleic acids, including Aptamers, also bind to PF4 and enhance PF4 binding to platelets. Systematic assessment of RNA and DNA constructs, as well as 4 Aptamers of different lengths and secondary structures, revealed that increasing length and double-stranded segments of nucleic acids augment complex formation with PF4, while single nucleotides or single-stranded polyA or polyC constructs do not. Aptamers were shown by circular dichroism spectroscopy to induce structural changes in PF4 that resemble those induced by heparin. Moreover, heparin-induced anti-human-PF4/heparin antibodies cross-reacted with human PF4/nucleic acid and PF4/aptamer complexes, as shown by an enzyme Immunoassay and a functional platelet activation assay. Finally, administration of PF4/44mer-DNA protein C aptamer complexes in mice induced anti-PF4/aptamer antibodies, which cross-reacted with murine PF4/heparin complexes. These data indicate that the formation of anti-PF4/heparin antibodies in postoperative patients may be augmented by PF4/nucleic acid complexes. Moreover, administration of therapeutic Aptamers has the potential to induce anti-PF4/polyanion antibodies and a prothrombotic diathesis.

Figures
Products